Showing 161-170 of 1914 results for "".
Pre-joy and Type 2 Fun for the Dermatologist
https://practicaldermatology.com/topics/practice-management/pre-joy-and-type-2-fun-for-the-dermatologist/21005/The Three-Step Journey to Your Practice Door
https://practicaldermatology.com/topics/practice-management/the-three-step-journey-to-your-practice-door/21030/Patients travel the same steps to every practice. Here's how to get them to your door.Journal Club: Colloidal Oat for Prevention and Treatment
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-colloidal-oat-for-prevention-and-treatment/32407/Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, and Editorial Board member Lawrence Eichenfield, MD, FAAD, discuss a study demonstrating the benefits of oat for infant skincare, especially for the treatment and mitigation of atopic dermatitis.Just Take a Knee and Sit this One Out
https://practicaldermatology.com/topics/practice-management/just-take-a-knee-and-sit-this-one-out/20569/The Big Idea: Jeanine Downie, MD on Practice Planning
https://practicaldermatology.com/topics/practice-management/the-big-idea-jeanine-downie-md-on-practice-planning/19279/Dr. Downie discusses the benefits of a defined benefits pension plan and why she incorporated it into her practice plan from the start. Featured in "What's The Big Idea."The Big Idea: Jeanine Downie, MD on Hiring Decisions
https://practicaldermatology.com/topics/practice-management/the-big-idea-jeanine-downie-md-on-hiring-decisions/19277/Dr. Downie discusses the important considerations in hiring, including how to spot the best candidates and ensure a top-notch patient experience. Featured in "What's the Big Idea"Phase 2 and 3 Trials of JAK Inhibitors For Atopic Dermatitis: A Review
https://practicaldermatology.com/topics/atopic-dermatitis/phase-2-and-3-trials-of-jak-inhibitors-for-atopic-dermatitis-a-review/23265/A number of drugs in development show promise for one of the most challening skin diseases.JAK Inhibitors in Hidradenitis Suppurativa: A Systematic Review
https://practicaldermatology.com/topics/feature/jak-inhibitors-in-hidradenitis-suppurativa-a-systematic-review/29887/Hidradenitis suppurativa (HS) is a chronic, disfiguring, debilitating, inflammatory disorder that is characterized by inflammatory nodules, abscesses, fistulae/ sinus tracts, and scarring to the axilla, inframammary folds, and groin.DermWireTV: Pfizer, AbbVie JAKs for AD; Spray-on-Skin; Lubriderm Scholarships
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-pfizer-abbvie-jaks-for-ad-spray-on-skin-lubriderm-scholarships/20043/For the treatment of refractory moderate-to-severe atopic dermatitis, FDA has approved Pfizer’s Cibinqo (abrocitinib) for adults and AbbVie’s Rinvoq (upadacitinib) for patients 12 and older. Researchers at the Houston Methodist Research Institute have paired their patented RNA technologies with AvitWomen in Dermatology With S. Manjula Jegasothy, MD
https://practicaldermatology.com/topics/practice-management/women-in-dermatology-with-s-manjula-jegasothy-md/23173/